Press Releases

Press Release: Friday June 22nd, 2001
TheraLife^® Incorporated to present at "Bio 2001" conference.

San Diego, June 26th, 2001 - TheraLife^® Inc. today announced that TheraLifetm Inc., has been selected to present at the "Bio 2001" conference in San Diego on June 24-27, 2001. Dr. Lily Yang and Dr. Armin Ramel will be presenting at the Technology Partnering Forum on June 26 th , 2001 from 2-5 pm as part of the Device, Delivery, and Diagnostics portion of the conference.

TheraLife^® is a botanical drug company with a drug enhancement system (DES) - the TheraLife^® Enhancer. This technology is a multi-component system that combines the benefits of faster, safer delivery with reduced side effects.

"There are many areas in which drug performance could be improved", says Dr. Yang. These areas include insufficient solubility; toxicity; slow pharmacokinetics (slow in getting into the blood stream); and molecules too large for oral administered, which must be delivered via IV (intravenous) or IM (intramuscular) injection.

Large molecules are broken down by enzymes in the stomach and gut, rendering them no longer active. This is particularly true for biopharmaceuticals, e.g., proteins, which are naturally occurring large molecules. Insulin is such an example. It must be injected intramuscularly. Diabetic patients need insulin daily, sometimes several times a day. There are now companies delivering insulin by aerosol methods, i.e. producing small droplets by spraying the drug into the lungs or buccal area (the mucosal area in the back of the throat). However, the lung cells and buccal cells have limited capacity for the absorption of the drug molecule.

There are many pharmaceutical compounds chemically designed to facilitate absorption. In contrast, TheraLife^® Inc. (Los Altos, Calif.) has come up with a unique multi-component formulation specifically designed to: 1) Increase cellular metabolism, therefore facilitating drug absorption; 2) Increase microcirculation, therefore reaching areas that have poor or decreased circulation; 3) Protect kidney and liver cells. TheraLife^® is positioned to leverage this technology to enhance drug absorption to be faster, safer and with lower side effects.

To validate this drug enhancement system (DES), TheraLife^® completed a Stage 1 double blind, placebo controlled clinical trial using a combination of this technology with the TheraLife^® Eye specific formula for the treatment and relief of 'dry eyes'. The eye has poor circulation and it is very difficult for oral medications to reach it. The company plans to submit clinical trial results to FDA, establish medical claims, and develop corporate partnerships for its marketing and distribution.

Notice: This release and oral statements made from time to time by TheraLife^® representatives concerning the same subject matter may contain so-called "forward-looking statements." These statements can be identified by introductory words such as "expects", "plans", "will", "estimates", "forecasts", "projects", or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing regulatory submissions and approvals, development programs, etc. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and other of which are not. No forward-looking statement is a guarantee of future results or events, and one should avoid paying undue reliance on such statements.

COMPANY CONTACT:
James Alston
E-mail: Jalston@theralife.com
(650) 917-1989
(650) 917-1434 fax
101 First Street
Los Altos, CA 94022
www.theralife.com